An interventional study of tAN device in Sickle Cell Disease, sponsored by Emory University. Recruiting at 1 site in United States. Open to participants aged 7 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Emory University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Anemia, Sickle Cell by Emory University — 4 open to participants now, 6 under way, none of them phase 3. Anemia, Sickle Cell · Emory University.
Among the 29 studies in Anemia, Sickle Cell by Emory University, this one is the 17th largest by planned enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2025, is one of 12 with no phase, and was the 28th registered.
1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.
Browse Anemia, Sickle Cell studies →4 of the 29 studies in Anemia, Sickle Cell by Emory University are open now, in 1 country. Recruiting first, the newest first:
Emory University · Sites in United States
Ages 8–18
Emory University · Sites in United States
Ages 12–18
Emory University · Sites in United States
Ages 7–21
By country, each count listing its studies:
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: 7 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 7 · Phase 4 1
First in 2005; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 40 across 770 interventional studies indexed under Anemia, Sickle Cell.
Median enrollment 24 across the 25 interventional studies, 20 across the 4 observational. Of the 20 that completed or were terminated, 9 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
Emory University is the lead sponsor of 1,406 studies on the registry; 224 are open to participants now.
Of its 238 completed or terminated interventional studies of FDA-regulated products, 179 (75%) have results posted.
4 of the studies in Anemia, Sickle Cell by Emory University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04018937Emory UniversityEarly Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation | 2026-11 |
| NCT07090668Emory UniversityTrans-auricular Nerve Stimulation as an Innovative Approach to the Treatment of Pain in Pediatric Patients Suffering From Sickle Cell Disease | 2027-01 |
| NCT03924401Emory UniversityAcute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant | 2027-03-01 |
| NCT06691867Emory UniversityIntegrative Training Program for Pediatric Sickle Cell Pain | 2027-08 |
Add all 4 to your calendar (.ics) → With an account.
Among the 29 studies in Anemia, Sickle Cell by Emory University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to evaluate the effects of transauricular vagus and trigeminal nerve stimulation on the treatment of pain in children with Sickle Cell Disease.
The vagus nerve, the body's longest cranial nerve, extends from the brainstem to deep regions of the gastrointestinal tract and plays a vital role in regulating parasympathetic activity across multiple organ systems, including the cardiovascular, respiratory, immune, and nervous systems. Since the early 2000s, vagal nerve stimulation (VNS) has been explored as a therapeutic tool across various diseases, particularly for pain management. VNS can reduce pain by three primary mechanisms: 1) suppressing systemic inflammation, 2) modulating central pain-processing pathways, and 3) alleviating depressive symptoms, which are known to intensify the experience of pain.
Sickle cell disease (SCD) is a genetic blood disorder caused by a point mutation in the β-globin gene, resulting in the production of abnormal hemoglobin (HbS). This leads to polymerization of hemoglobin under low-oxygen conditions, which causes red blood cells to become rigid and sickle-shaped. These malformed cells damage blood vessels and adhere to endothelial surfaces, resulting in vaso-occlusion and impaired blood flow. The subsequent ischemia-reperfusion injury provokes widespread inflammation and produces both acute pain episodes and chronic pain syndromes, often beginning in childhood and persisting throughout life.
The current standard for managing SCD-related pain often involves chronic opioid use, which can lead to dependence, tolerance, and serious side effects. Given the ongoing opioid crisis, there is an urgent need for non-pharmacologic alternatives that are safe, effective, and scalable.
This study proposes the use of transcutaneous auricular vagal nerve stimulation (taVNS) as well as trigeminal auricular nerve stimulation (TAN) -non-invasive methods that stimulates vagal afferents and branches of the trigeminal nerve through the ear-to treat pain in pediatric patients with SCD. taVNS is notable for its excellent safety profile, with minimal to no adverse effects reported in clinical studies. It is a multimodal pain management tool, acting simultaneously on immune, neurologic, and psychological pathways that contribute to pain in SCD.
The innovative aspect of this study lies in its application of a non-invasive, neuroimmune-modulating therapy in a pediatric population with complex pain needs. By potentially reducing the frequency and severity of pain episodes and thereby decreasing reliance on opioids, tAN could transform the clinical approach to pain management in SCD. Ultimately, this research aims to provide a safe, sustainable, and accessible intervention that addresses both the biological and psychosocial dimensions of pain in children and adolescents with SCD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will serve as their own controls. Using chart review, we will collect data from each participant's previous admission for a pain crisis during which they did not receive tAN treatment and compare it to their current admission, during which they are being treated with tAN
Subjects admitted to CHOA with SCD pain crisis.
Device: tAN device
Sparrow Link tAN device from Spark Biomedical, a non-invasive, adhesive earpiece placed over branches of the trigeminal nerve and vagus nerve near the tragus and mastoid around the ear. The stimulation level is titrated by the investigator to a perceptible but comfortable intensity. Patients cannot adjust the settings themselves, though adjustments can be made upon request. The device consists of a disposable earpiece connected by a cable to a battery-powered controller (3 AAA batteries). It emits a biphasic, rectangular waveform with a 100 µs interphase and a maximum output of 95V.
Feasibility: Completion Rate
Completion rate will be calculated by dividing the number of subjects who successfully used tAN for the duration of the trial, divided by the total number of subjects who participated in the trial. Subjects who prematurely opt to interrupt their participation in the study will not be included in the cohort of patients who successfully completed the study
Time frame: Through study completion (an average of 3-7 days)
Stimulation tolerability
Stimulation tolerability will be evaluated daily during hospitalization by asking participants to describe any sensations experienced in response to percutaneous stimulation. Participants will be encouraged to express the sensation in their own words. The investigator will then further clarify the nature of the sensation-such as whether it feels like burning, tingling, or stabbing-to better characterize the participant's experience.
Time frame: Baseline, everyday throughout the study (an average of 3-7 days)
Acceptability of intervention
Acceptability of intervention measure will be assessed using a standardized 4 item questionnaire.
Time frame: Baseline, everyday throughout the study (an average of 3-7 days)
Wong-Baker FACES
The Wong-Baker FACES Pain Rating Scale is a widely used tool to help individuals-especially children-communicate their level of pain. It uses a series of six cartoon faces, ranging from a happy face at 0 ("No Hurt") to a crying face at 10 ("Hurts Worst"), allowing patients to point to the face that best describes their pain.
Time frame: Baseline, everyday throughout the study (an average of 3-7 days)
Functional Status Scale(FSS)
The FSS evaluates six functional domains: Mental Status, Sensory Function, Communication, Motor Function, Feeding, Respiratory Status Each domain is scored on a scale from 1 to 5. Total score range: 6 (best possible function) to 30 (worst possible function)
Time frame: Baseline, everyday throughout the study (an average of 3-7 days)
Change in Interleukin 6 (IL-6) levels
IL-6 is a pro-inflammatory cytokine involved in immune responses, inflammation, and infection. Typically \< 5 pg/mL in serum or plasma
Time frame: Baseline, end of the study (an average of 3-7 days)
Change in MCP-1
MCP-1 is a pro-inflammatory chemokine that recruits monocytes and other immune cells to sites of inflammation. In children, elevated MCP-1 levels are seen in conditions such as infections, inflammatory diseases Normal levels in healthy children are typically \<100-200 pg/mL
Time frame: Baseline, end of the study (an average of 3-7 days)
Change in Tumor necrosis factor (TNF-α)
TNF-α (Tumor Necrosis Factor Alpha) is a key pro-inflammatory cytokine involved in immune activation and systemic inflammation. Normal levels are typically \<10 pg/mL.
Time frame: Baseline, end of the study (an average of 3-7 days)
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Jan 2027, 17 months after the start.
Of 165 non-industry interventional studies with no phase under Anemia, Sickle Cell, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 54. This study's planned 17 months is below that.
Counting every sponsor, half of 173 studies reached it within 28 months; a quarter within 15 and three quarters within 49.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Jul 2026 → Jan 2027 and completion Jul 2026 → Jan 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.